{"entity":{"id":"nct02981368","kind":"trial","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","aka":[],"tldr":"A phase 2/3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.","summary":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer is a phase 2/3 interventional study registered as NCT02981368 by Progenics Pharmaceuticals, Inc., with 385 participants recorded, started 2016-11 and reaching its primary completion in 2018-07. Interventions recorded: 18F-DCFPyL Injection, PET/CT imaging. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Piflufolastat F-18 / Pylarify TruVu because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02981368","url":"https://clinicaltrials.gov/study/NCT02981368"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["pylarify"],"companies":["lantheus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02981368","phase":"2/3","setting":"A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)","sponsor":"Progenics Pharmaceuticals, Inc.","enrolled":385,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02981368/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/"}],"company":[{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/"}]}}